AB&B BIO-TECH-B (02627) rose over 7%. As of the time of writing, the stock was up 7.54%, trading at HKD 46.5, with a turnover of HKD 18.84 million. On the news front, the National Health Commission recently held its first press conference of 2026, where experts recommended that all individuals over 6 months of age without contraindications should receive an annual flu vaccination.
Guohai Securities pointed out that Huierkangxin is the first and only quadrivalent subunit influenza vaccine in China. Compared to split-virion vaccines, it offers advantages such as comprehensive protection, high purity of component antigens, and a lower risk of adverse reactions. The product was approved for domestic market launch in 2023 for individuals aged 3 and above, with an age expansion to those over 6 months planned for 2025. In 2024, it generated revenue of RMB 260 million, a year-on-year increase of 398%. As the company's first approved product, it is currently in a phase of rapid volume expansion, leading the consumption upgrade for influenza vaccines.
Guohai Securities stated that after years of research and development, the company has built a comprehensive vaccine development support platform and proprietary technology platform based on new technologies aligned with international trends. It is simultaneously advancing the development of innovative vaccines and the upgrade of traditional vaccines, resulting in a rich vaccine pipeline. Guided by unmet public health needs, the company is expanding into indications with high commercial potential. Beyond the two core products—the quadrivalent influenza virus subunit vaccine and the human diploid cell rabies vaccine—the company is actively developing 11 other vaccines to precisely address market gaps.
Comments